<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014026</url>
  </required_header>
  <id_info>
    <org_study_id>INCA08-KH/APACHE-1</org_study_id>
    <nct_id>NCT01014026</nct_id>
  </id_info>
  <brief_title>Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention</brief_title>
  <acronym>APACHE-1</acronym>
  <official_title>Human Papillomavirus DNA Testing Using Self-collected Samples for Cervical Cancer Screening: an Alternative Strategy for Unscreened Women?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Scientific Context&#xD;
&#xD;
      High-risk types of human papillomavirus (HPV) are the causative agents for cervical cancer.&#xD;
      Cervical cancer screening strategies rely on periodic Papanicolaou (Pap) testing. It's&#xD;
      well-known that this test has significantly contributed to the reduction of mortality and&#xD;
      morbidity due to cervical cancer. In France, it now seems that the screening strategy could&#xD;
      be optimized. The two main ways are to reach the 7 million underscreened women (mass&#xD;
      screening, self-sampling for HPV DNA testing) and to improve the screening test (HPV DNA&#xD;
      testing, computer-assisted cytology). Self-collected vaginal samples (SCVS) for HPV DNA&#xD;
      testing could be a relevant screening option: this technique appears reliable and it could&#xD;
      allow to reach women who are never or seldom screened. Currently, there is no French data on&#xD;
      the SCVS for HPV DNA testing.&#xD;
&#xD;
      The goal of this study is to determine the performance and acceptability of a&#xD;
      population-based strategy using self-collected vaginal samples for HPV DNA testing to reach&#xD;
      women who are not participating in cervical cancer screening.&#xD;
&#xD;
      Description of the project&#xD;
&#xD;
      This project (APACHE-1) is a part of a project called APACHE. APACHE-1 will be dedicated to&#xD;
      the SCVS technical validation and to the comparison between different transports medium. Nine&#xD;
      hundred women will be recruited from the 20 to 65 years consultants in the Tours University&#xD;
      Hospital (CHRU of Tours) and in the IRSA (health centre for routine medical checkup).&#xD;
&#xD;
      Each woman will collect 2 SCVS with a nylon flocked swab (Copan® microRheologics™). The first&#xD;
      SCVS will be put in a vial which contains a liquid medium. The second SCVS will be put in a&#xD;
      dry vial. Then during the speculum examination the physician will collect a cervical sample&#xD;
      with a Rovers® Cervex-Brush™ and then rinse it into a vial containing PréservCyt ™. A blind&#xD;
      HPV DNA testing and genotyping (Inno-LIPA HPV Genotyping ™ Extra) will be performed in the&#xD;
      virology laboratory of the CHRU of Tours on all samples (SCVSs and cervical samples performed&#xD;
      by a physician). The performance of the SCVS to detect cervical HPV infection will be&#xD;
      assessed (gold standard test = HPV DNA testing on cervical samples collected by the&#xD;
      physician).&#xD;
&#xD;
      In a second time (APACHE-2), the researchers will investigate to what extent offering home&#xD;
      obtained SCVS leads to participation of unscreened women. APACHE-2 will be registered on&#xD;
      Clinicaltrials as another project.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance between the three HPV tests</measure>
    <time_frame>End of the study</time_frame>
  </primary_outcome>
  <enrollment type="Actual">734</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <condition>Uterine Cervical Dysplasia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Screening test</intervention_name>
    <description>Two Vaginal self sampling devices and HPV test</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women between 20 and 65&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Menstruation&#xD;
&#xD;
          -  pregnant&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Vaccinated against HPV 16 and 18&#xD;
&#xD;
          -  Total Hysterectomy&#xD;
&#xD;
          -  treatment of CIN 1, 2 or 3&#xD;
&#xD;
          -  Abnormal smear in the past year&#xD;
&#xD;
          -  Smear in the past 2 years&#xD;
&#xD;
          -  Virgin&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken HAGUENOER</last_name>
    <role>Study Director</role>
    <affiliation>François Rabelais University, Public Health Laboratory, Tours, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRSA 37</name>
      <address>
        <city>La Riche</city>
        <zip>37521</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRSA 72</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Orthogénie, CHRU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie, CHRU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Association Paul Metadier</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>November 13, 2009</study_first_submitted>
  <study_first_submitted_qc>November 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2009</study_first_posted>
  <last_update_submitted>May 12, 2011</last_update_submitted>
  <last_update_submitted_qc>May 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>University Hospital, Tours</name_title>
    <organization>University Hospital, Tours</organization>
  </responsible_party>
  <keyword>Mass Screening</keyword>
  <keyword>Polymerase Chain Reaction</keyword>
  <keyword>Vaginal Smears</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

